An experimental gene-editing therapy that aims to lower bad cholesterol for the long-term after a single infusion is off to a ...
A one-time gene therapy for treating hypercholesterolaemia could lower up to 62 per cent 'bad' cholesterol in the blood, with ...
The VERVE-102 base editor appeared to be safe and reduce low-density lipoprotein cholesterol levels by up to 62 percent in a Phase I open-label, single-ascending dose trial.
Editing your genes to eliminate bad cholesterol and a new discovery that could change the playbook for Alzheimer's. Here are ...
Unraveling the role of interferon-stimulated neutrophils: A promising biomarker for immunotherapy efficacy and prognosis in gastric adenocarcinoma. Outcomes of patients by HER2 heterogeneity and gene ...
A single dose of an off-the-shelf gene-editing therapy leads to durable correction of the sickle cell disease-causing ...
Circio Holding has presented preclinical data at ASGCT demonstrating that its circVec circular RNA platform achieved up to 40 ...
The US Food and Drug Administration on Thursday approved the first gene therapy for inherited hearing loss, a one-time treatment that proved to be life-changing for a small number of children in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results